Smith & Nephew SNATS (NYSE:SNN) Cut to Buy at Wall Street Zen

Wall Street Zen lowered shares of Smith & Nephew SNATS (NYSE:SNN) from a strong-buy rating to a buy rating in a report issued on Monday morning.

A number of other equities research analysts also recently commented on the company. Canaccord Genuity Group reduced their target price on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, October 8th. Finally, Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Trading Up 0.2%

NYSE SNN opened at $32.84 on Monday. The business’s fifty day simple moving average is $33.97 and its 200-day simple moving average is $33.86. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 52 week low of $23.69 and a 52 week high of $38.79.

Institutional Trading of Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC boosted its holdings in shares of Smith & Nephew SNATS by 11.7% in the third quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock valued at $139,000 after acquiring an additional 401 shares in the last quarter. Versant Capital Management Inc raised its holdings in Smith & Nephew SNATS by 5.0% during the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock worth $323,000 after purchasing an additional 423 shares in the last quarter. Vise Technologies Inc. lifted its position in Smith & Nephew SNATS by 4.7% in the third quarter. Vise Technologies Inc. now owns 9,642 shares of the medical equipment provider’s stock worth $350,000 after purchasing an additional 437 shares during the period. Quadrant Capital Group LLC boosted its stake in Smith & Nephew SNATS by 3.6% during the 3rd quarter. Quadrant Capital Group LLC now owns 12,757 shares of the medical equipment provider’s stock valued at $463,000 after purchasing an additional 440 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in Smith & Nephew SNATS by 4.6% during the 3rd quarter. First Trust Advisors LP now owns 10,532 shares of the medical equipment provider’s stock valued at $382,000 after purchasing an additional 459 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.